Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma

This study has been completed.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Craig L Slingluff, Jr, University of Virginia Identifier:
First received: August 4, 2004
Last updated: December 18, 2014
Last verified: December 2014
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Estimated Study Completion Date: No date given
  Primary Completion Date: February 2007 (Final data collection date for primary outcome measure)
No publications provided by University of Virginia

Publications automatically indexed to this study by Identifier (NCT Number):